Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.
Chris Mazzolini
Advertisement
Articles by Chris Mazzolini
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Investigator Onboarding Remains a Major Challenge in Clinical Trial Contracting
2
Cybersecurity in Service Provider Selection and Qualification: A Critical Aspect of Modern Clinical Research
3
IQVIA and Veeva Outline Strategy for Supporting Decentralized and Hybrid Trials
4
How FDA’s Focus on Overall Survival Redefines Trial Success
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
